MLAB earnings analysis
What we found in MLAB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Mesa reported $60.138 million of revenue and $0.49 diluted EPS for the quarter. Revenue missed the $60.667 million consensus estimate, while operating margin improved sequentially to 5.2%; supplied earnings data also showed adjusted EPS of $2.68 versus a $2.40 estimate. Cash generation weakened sharply, with free cash flow of approximately $0.884 million versus $14 million in the prior quarter, and management deferred full-year guidance until November.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue missed consensus; margin improved sequentially
- Revenue was $60.138 million, approximately 1.2% below the $60.667 million consensus estimate and below the prior-quarter $64 million level. Gross margin was 62.0%, up from 61.5% in the prior quarter but below 66.2% in 2025Q4.
- Operating margin recovered sequentially
- Operating margin improved to 5.2% from 2.4% in 2025Q4, although it remained below the 12.3% level reported in 2026Q3.
- Adjusted EPS beat, but GAAP earnings lagged
- Diluted EPS was $0.49, while the supplied earnings data reported adjusted EPS of $2.68 versus a $2.40 estimate, a 11.67% adjusted EPS beat. The filing analysis attributed the difference between operating improvement and GAAP earnings to nonoperating expense, which reduced net income by 40.3%.
- BPD and CS supported growth
- BPD and CS were identified as growth drivers, while SDC execution issues pressured sales and China weakness constrained CG. Segment revenue amounts were not disclosed in the supplied filing extract.
- Free cash flow declined materially
- Free cash flow was approximately $0.884 million, sharply below $14 million in the prior quarter and $18 million in 2026Q3, indicating materially weaker cash conversion despite positive reported earnings.
- Controls and market-risk profile stable
- The company reported no material changes to market-risk exposure during the three months ended June 30, 2026, and management concluded disclosure controls were effective as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nonoperating expense pressured GAAP earnings
- The filing states that nonoperating expense drove a 40.3% decline in net income, creating a significant gap between operating improvement and GAAP diluted EPS of $0.49.
- Cash conversion deteriorated
- Free cash flow fell to approximately $0.884 million from $14 million in the prior quarter, increasing the risk that earnings are not converting into cash at the recent historical rate.
- Existing operating risks remain
- Management reported no material changes to the risk factors in its March 31, 2026 Form 10-K during the three months ended June 30, 2026. Existing risks nevertheless included SDC execution pressure and China weakness affecting CG, with no quantitative segment data provided in the filing extract.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.49
- Gross margin
- 62.0%
- Operating margin
- 5.2%
What they said about what is next.
No quantitative guidance was provided in the filing. Management indicated full-year guidance will be provided in November alongside first-half results; no updated FY2027 outlook was issued.
The filing reads about the same as the one before it.
What came before.
- 10-K · June 2, 2026
- Mesa Laboratories reported a 3.4% revenue growth to $249.1M for fiscal year 2026, attributed to strong performances in its Sterilization and Disinfection Control and Calibration Solutions divisions. The company's…
- 10-Q · February 3, 2026
- Mesa Laboratories reported quarterly revenue of $65,126,000 (up from $62,840,000 a year ago) and produced net income of $3,630,000 for the three months ended December 31, 2025 (versus a net loss of $1,676,000 in the…
- 10-Q · August 5, 2025
- Mesa Laboratories reported quarter revenue of $59,543,000 (up $1,373,000 vs. $58,170,000 a year ago) and GAAP diluted EPS of $0.85 (vs. $0.62 prior year). Gross margin compressed to ~62.0% while operating income…
- 10-K · May 28, 2025
- Mesa Laboratories positions itself as a niche, high-margin supplier of life-science tools and quality-control solutions, growing organically (consumables/higher-usage products) and inorganically via targeted…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MLAB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever